Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 11, 2011 - Issue 11
Submit an article Journal homepage
29
Views
3
CrossRef citations to date
0
Altmetric
Review

End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era

Enrico Franceschi Department of Medical Oncology, Bellaria-Maggiore Hospital, Bologna, Italy; Department of Medical Oncology, Bellaria-Maggiore Hospital, Bologna, Italy
,
Raffaele Agati Department of Neuroradiology, Bellaria-Maggiore Hospital, Bologna, Italy; Department of Neuroradiology, Bellaria-Maggiore Hospital, Bologna, Italy
&
Alba A Brandes Department of Medical Oncology, Bellaria-Maggiore Hospital, Bologna, Italy;[email protected]
Pages 1713-1717 | Published online: 10 Jan 2014

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Pasquale De Bonis, Francesco Doglietto, Carmelo Anile, Angelo Pompucci & Annunziato Mangiola. (2012) Electric fields for the treatment of glioblastoma. Expert Review of Neurotherapeutics 12:10, pages 1181-1184.
Read now

Articles from other publishers (2)

Vincenzo Di Nunno, Lidia Gatto, Alicia Tosoni, Stefania Bartolini & Enrico Franceschi. (2023) Letter concerning “Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival”: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma. Neuro-Oncology 25:8, pages 1546-1547.
Crossref
Umut Demirci, Gulnihal Tufan, Bilge Aktas, Ozan Balakan, Ahmet Alacacioglu, Faysal Dane, Huseyin Engin, M. Ali Kaplan, Yusuf Gunaydin, Nuriye Y. Ozdemir, I. Tugba Unek, Halit Karaca, Tulay Akman, Ozlem U. Sonmez, Ugur Coskun, Hakan Harputluoglu, Alper Sevinc, Onder Tonyali, Suleyman Buyukberber & Mustafa Benekli. (2013) Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Journal of Cancer Research and Clinical Oncology 139:5, pages 829-835.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.